U.S. Food and Drug Administration (FDA) Patient-Focused Drug Development
The FDA wants to hear from you about your condition and your treatments. The FDA is interested in obtaining patient input on the most common female sexual dysfunction, female sexual interest/arousal disorder (FSIAD), its signs, symptoms, daily impacts that matter most to patients, and current available approaches to treat FSIAD.
You can contribute in three ways:
- Attend the public meeting in person
- Participate in the live meeting webcast
- Share comments through the public docket
FDA Public Meeting will be held on October 27th, 2014 from 12:00 – 5:00 p.m. You can view the webcast of the event on that day, or attend in person. You can also view the October 28 webcast of the workshop, or attend in person.
Where:
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Great Room
Silver Spring, Maryland 20993
For each of these topics, a panel of patients and patient representatives/advocates will present comments to begin the dialogue and will be followed by a facilitated discussion inviting comments from all patients and patient representatives in the audience.
If you are interested in providing comments as part of the initial panel discussion, indicate so during the registration process. Panelists will be confirmed prior to the meeting.
Webcast participants will also have an opportunity to provide input through webcast comments.
FDA is also conducting a scientific workshop on female sexual dysfunction:
October 28, 2014 from 8:30 a.m. – 5:00 p.m.
Find more information and register
*Registration closes on October 20, 2014